000			01897nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aDrug Metabolism/Transport and Pharmacokinetics
546			_aEnglish[eng]
650			_atofacitinib||dose-dependent pharmacokinetics||hepatic and intestinal first-pass effect||rats||catalposide||in vitro human metabolism||UDP-glucuronosyltransferase||sulfotransferase||carboxylesterase||celecoxib||drug–drug interaction||fluorescence||HPLC||metabolism||repaglinide||HSG4112||anti-obesity agent||stereoselectivity||pharmacokinetics||compound K||protopanaxadiol (PPD)||biliary excretion||intestinal metabolism||Carthamus tinctorius extract||notoginseng total saponins||comparative pharmacokinetic study||large volume direct injection||compatibility mechanism||mertansine||human hepatocytes||cytochrome P450||UDP-glucuronosyltransferases||sodium-glucose cotransporter 2 (SGLT2) inhibitors||DWP16001||kidney distribution||inhibition mode||diabetes||transporter-enzyme interplay||influx transporter||efflux transporter||physiologically based pharmacokinetic model||cytochrome P450 enzymes||tiropramide||healthy Korean subjects||modeling||population pharmacokinetic||quercetin||breast cancer resistance protein||inhibitor||prazosin||sulfasalazine||kinetic analysis||food–drug interactions||Caco-2||EpiIntestinal||first-pass||P-gp||BCRP||drug transporter||CYP3A4||oral availability||automatization||drug absorption||drug dosing||head-and-neck cancer||real-time measurements||taxanes||tissue engineering||UHPLC-MS/MS||metformin||verapamil||drug interaction||organic cation transporter 2||renal excretion||acute renal failure||gentamicin||cisplatin||hepatic CYP3A1(23)||creatinine clearance||renal clearance||nonrenal clearance
700			_aSong, Im-Sook
856			_uhttps://mdpi.com/books/pdfview/book/4688
942			_cEB
999			_c32265 _d32265